Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration
“We believe that our unique cooperation and the complementary skill sets of both companies will offer a valuable alternative for innovation in the demanding field of ion channel based drugs and will industrialize the process for the generation of novel drugs for high medical needs”, added Stefan Lohmer, Chairman and CEO of Axxam.
Jean-Pierre Obrecht, CEO of Polyphor said: “We have selected Axxam as the preferred partner because of its strong expertise in assay development and HTS, in particular in the field of ion-channels. This capability will allow Polyphor to efficiently exploit the potential of its proprietary drug development platforms and accelerate the identification of novel research programs.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.